Bactiguard Holding Past Earnings Performance
Past criteria checks 0/6
Bactiguard Holding's earnings have been declining at an average annual rate of -41.5%, while the Medical Equipment industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 5.3% per year.
Key information
-41.5%
Earnings growth rate
-41.1%
EPS growth rate
| Medical Equipment Industry Growth | 6.2% |
| Revenue growth rate | 5.3% |
| Return on equity | -17.1% |
| Net Margin | -23.7% |
| Next Earnings Update | 06 Feb 2025 |
Recent past performance updates
Recent updates
Bactiguard Holding AB (publ) (STO:BACTI B) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Oct 08
Bactiguard Holding (STO:BACTI B) Is Making Moderate Use Of Debt
Sep 03Bactiguard Holding AB (publ)'s (STO:BACTI B) 30% Share Price Surge Not Quite Adding Up
Feb 06Bactiguard Holding (STO:BACTI B) Is Carrying A Fair Bit Of Debt
Jan 12Is Bactiguard Holding (STO:BACTI B) Using Debt In A Risky Way?
Jul 02Bactiguard Holding AB (publ)'s (STO:BACTI B) Business Is Trailing The Industry But Its Shares Aren't
May 05Bactiguard Holding (STO:BACTI B) Has Debt But No Earnings; Should You Worry?
Feb 15Does Bactiguard Holding (STO:BACTI B) Have A Healthy Balance Sheet?
Sep 15Is Bactiguard Holding (STO:BACTI B) Using Debt Sensibly?
Jun 03Does Bactiguard Holding (STO:BACTI B) Have A Healthy Balance Sheet?
Jan 22Is Bactiguard Holding (STO:BACTI B) Using Too Much Debt?
Feb 26Do Institutions Own Bactiguard Holding AB (publ) (STO:BACTI B) Shares?
Jan 22Did Bactiguard Holding AB (publ) (STO:BACTI B) Insiders Buy Up More Shares?
Dec 27Bactiguard Holding (STO:BACTI B) Has A Pretty Healthy Balance Sheet
Nov 22
Revenue & Expenses Breakdown
How Bactiguard Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 237 | -56 | 194 | 0 |
| 30 Jun 24 | 215 | -76 | 188 | 0 |
| 31 Mar 24 | 202 | -126 | 220 | 0 |
| 31 Dec 23 | 204 | -138 | 221 | 0 |
| 30 Sep 23 | 211 | -125 | 227 | 0 |
| 30 Jun 23 | 224 | -109 | 225 | 0 |
| 31 Mar 23 | 233 | -58 | 193 | 0 |
| 31 Dec 22 | 227 | -53 | 188 | 0 |
| 30 Sep 22 | 209 | -64 | 178 | 0 |
| 30 Jun 22 | 193 | -66 | 166 | 0 |
| 31 Mar 22 | 186 | -65 | 153 | 0 |
| 31 Dec 21 | 172 | -59 | 141 | 0 |
| 30 Sep 21 | 216 | -44 | 153 | 0 |
| 30 Jun 21 | 203 | -50 | 148 | 0 |
| 31 Mar 21 | 170 | -38 | 119 | 0 |
| 31 Dec 20 | 177 | -38 | 115 | 0 |
| 30 Sep 20 | 155 | -26 | 91 | 0 |
| 30 Jun 20 | 187 | 14 | 88 | 0 |
| 31 Mar 20 | 206 | 9 | 108 | 0 |
| 31 Dec 19 | 190 | 16 | 104 | 0 |
| 30 Sep 19 | 155 | 9 | 108 | 0 |
| 30 Jun 19 | 128 | -15 | 106 | 0 |
| 31 Mar 19 | 149 | -10 | 115 | 0 |
| 31 Dec 18 | 150 | -15 | 115 | 0 |
| 30 Sep 18 | 160 | -10 | 105 | 0 |
| 30 Jun 18 | 159 | -10 | 105 | 0 |
| 31 Mar 18 | 143 | -15 | 96 | 0 |
| 31 Dec 17 | 151 | -3 | 94 | 0 |
| 30 Sep 17 | 142 | -10 | 93 | 0 |
| 30 Jun 17 | 142 | -10 | 93 | 0 |
| 31 Mar 17 | 140 | -12 | 92 | 0 |
| 31 Dec 16 | 124 | -27 | 93 | 0 |
| 30 Sep 16 | 116 | -39 | 82 | 0 |
| 30 Jun 16 | 139 | -32 | 84 | 0 |
| 31 Mar 16 | 133 | -34 | 93 | 0 |
| 31 Dec 15 | 135 | -27 | 98 | 0 |
| 30 Sep 15 | 120 | -39 | 106 | 0 |
| 30 Jun 15 | 87 | -61 | 105 | 0 |
| 31 Mar 15 | 88 | -95 | 100 | 0 |
| 31 Dec 14 | 95 | -111 | 94 | 0 |
| 30 Sep 14 | 137 | -60 | 91 | 0 |
| 30 Jun 14 | 143 | -50 | 93 | 0 |
| 31 Mar 14 | 136 | -20 | 85 | 0 |
| 31 Dec 13 | 129 | -3 | 80 | 0 |
Quality Earnings: BACTI B is currently unprofitable.
Growing Profit Margin: BACTI B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BACTI B is unprofitable, and losses have increased over the past 5 years at a rate of 41.5% per year.
Accelerating Growth: Unable to compare BACTI B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BACTI B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Return on Equity
High ROE: BACTI B has a negative Return on Equity (-17.09%), as it is currently unprofitable.